Mesenchymal Stem Cells Attenuate Hypoxic Pulmonary Vasoconstriction by a Paracrine Mechanism

Patel, Ketan M.; Crisostomo, Paul R.; Lahm, Tim; Markel, Troy A.; Herring, Christine M.; Wang, Meijing; Meldrum, Kirstan K.; Lillemoe, Keith D.; Meldrum, Daniel R.

doi:10.1016/j.jss.2006.11.006

Cited by 58 publications

(32 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some feel that stem cells differentiate into specific end-organ cells, which then become incorporated into the tissue to increase postinjury functional recovery (19). However, others have shown in cardiac, pulmonary, and renal tissue that protection from injury can be achieved in the absence of stem cell differentiation, thereby suggesting that stem cells aid native tissues via cell-cell interactions or via the release of protective paracrine substances during their transit through injured tissue (25,33,36,39). Many studies have applied stem cell therapy in the postischemic setting and have seen mixed results.…”

Section: Discussionmentioning

confidence: 99%

VEGF is critical for stem cell-mediated cardioprotection and a crucial paracrine factor for defining the age threshold in adult and neonatal stem cell function

Markel¹,

Wang²,

Herrmann³

et al. 2008

American Journal of Physiology-Heart and Circulatory Physiology

Self Cite

136

100

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

VEGF is critical for stem cell-mediated cardioprotection and a crucial paracrine factor for defining the age threshold in adult and neonatal stem cell function

Markel¹,

Wang²,

Herrmann³

et al. 2008

American Journal of Physiology-Heart and Circulatory Physiology

Self Cite

136

100

View full text Add to dashboard Cite

show abstract

“…During chronic hypoxia, MSCs may restore lung vascular homeostasis by inhibiting inflammation and vascular remodeling, thereby promoting vascular stability or they may potentially contribute to vessel wall remodeling (16). Significantly, MSCs have been shown to release growth factors when stressed by hypoxia in vitro (51,60), and as discussed by Foronjy and Majka, understanding the lung microenviroment is important because the endogenous MSC pool may react in opposing ways to different environmental cues (27).…”

Section: Role Of Mscs In Lung Diseasementioning

confidence: 99%

MSC Microvesicles for the Treatment of Lung Disease: A New Paradigm for Cell-Free Therapy

Sdrimas

Kourembanas

2014

Antioxidants & Redox Signaling

View full text Add to dashboard Cite

Significance: Bronchopulmonary dysplasia (BPD), also known as chronic lung disease of infancy, is a major complication of preterm birth that, despite improvements in neonatal respiratory support and perinatal care, remains an important cause of morbidity and mortality, often with severe adverse neurodevelopmental sequelae. Even with major advances in our understanding of the pathogenesis of this disease, BPD remains essentially without adequate treatment. Recent Advances: Cell-based therapies arose as a promising treatment for acute and chronic lung injury in many experimental models of disease. Currently, more than 3000 human clinical trials employing cell therapy for the treatment of diverse diseases, including cardiac, neurologic, immune, and respiratory conditions, are ongoing or completed. Among the treatments, mesenchymal stem cells (MSCs) are the most studied and have been extensively tested in experimental models of BPD, pulmonary hypertension, pulmonary fibrosis, and acute lung injury. Critical Issues: Despite the promising potential, MSC therapy for human lung disease still remains at an experimental stage and optimal transplantation conditions need to be determined. Although the mechanism of MSC action can be manifold, accumulating evidence suggests a predominant paracrine, immunomodulatory, and cytoprotective effect. Future Directions: The current review summarizes the effect of MSC treatment in models of lung injury, including BPD, and focuses on the MSC secretome and, specifically, MSC-derived microvesicles as potential key mediators of therapeutic action that can be the focus of future therapies. Antioxid. Redox Signal. 21, 1905Signal. 21, -1915

show abstract

“…21 There are a large number of therapies that have been proven useful in decreasing pulmonary arterial pressure, improving exercise tolerance and quality of life, but an effective therapy with a long-term outcome is lacking. 1,8, 22 In recent years, studies have shown that endothelial dysfunction is an inevitable feature and an early event in the pathogenesis of PH. 8, 23 As reported, inflammatory mechanisms Figure 4.…”

Section: Discussionmentioning

confidence: 99%

“…24, 25 Growth factors have been proven to have a vasodilatory effect on the vasculature, and VEGF has been shown to cause pulmonary vasodilation. 22 For these reasons, regenerative methods and gene therapy have been drawing considerable attention to the breaking of the vicious cycle of PH.…”

Section: Discussionmentioning

confidence: 99%

Effects of Autologous Bone Marrow Mononuclear Cells Implantation in Canine Model of Pulmonary Hypertension

Luan

Zhang

Wei

et al. 2012

Circ J

View full text Add to dashboard Cite

Mesenchymal Stem Cells Attenuate Hypoxic Pulmonary Vasoconstriction by a Paracrine Mechanism

Cited by 58 publications

References 36 publications

VEGF is critical for stem cell-mediated cardioprotection and a crucial paracrine factor for defining the age threshold in adult and neonatal stem cell function

VEGF is critical for stem cell-mediated cardioprotection and a crucial paracrine factor for defining the age threshold in adult and neonatal stem cell function

MSC Microvesicles for the Treatment of Lung Disease: A New Paradigm for Cell-Free Therapy

Effects of Autologous Bone Marrow Mononuclear Cells Implantation in Canine Model of Pulmonary Hypertension

Contact Info

Product

Resources

About